Therapy News and Research

RSS

EMR improves physicians' compliance with portal image review

The use of an electronic medical record (EMR) for reviewing portal images dramatically improves compliance with timeliness and record keeping, according to a study in the July issue of the Journal of the American College of Radiology.

3 Jul 2012

Prostate cancer patients with CVD are 52% more likely to regret their treatment choices

Prostate cancer patients with cardiovascular disease were 52 per cent more likely to regret their treatment choices than men without problems with their heart or veins, according to a study published in the July issue of the urology journal BJUI International.

3 Jul 2012

Researchers use mouse model of autism to treat CTD

Using a mouse model of autism, researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have successfully treated an autism spectrum disorder characterized by severe cognitive impairment.

3 Jul 2012

NOTCH1 signaling promotes T-cell acute lymphoblastic leukemia-initiating cell regeneration

Research suggests that patients with leukemia sometimes relapse because standard chemotherapy fails to kill the self-renewing leukemia initiating cells, often referred to as cancer stem cells. In such cancers, the cells lie dormant for a time, only to later begin cloning, resulting in a return and metastasis of the disease.

3 Jul 2012

Researchers identify new gene target for leukemia therapy

Researchers at the University of Cincinnati (UC) Hoxworth Blood Center have discovered a new gene target for leukemia therapy.

3 Jul 2012

GRP78 plays an important role in breast cancers that respond to anti-estrogen therapy

Researchers at Georgetown Lombardi Comprehensive Cancer Center have uncovered a single molecule they say is a major determinant of resistance to anti-estrogen therapy used to treat or prevent breast cancer in high-risk women.

3 Jul 2012

FDA accepts BLA filing and grants Priority Review to ThromboGenics' ocriplasmin

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it has officially accepted the filing of the Biologics License Application for ocriplasmin intravitreal injection, 2.5 mg/ml and granted it Priority Review.

3 Jul 2012

Imaging PR status may help identify tumor response to endocrine therapy

Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage.

3 Jul 2012

Study demonstrates effectiveness of combination therapy for breast cancer cells in vitro

A study conducted at Boston University School of Medicine (BUSM) demonstrates an effective combination therapy for breast cancer cells in vitro.

3 Jul 2012

Muhammad Ali Parkinson Center receives $3M donation from Celebrity Fight Night

The Muhammad Ali Parkinson Center at St. Joseph's Hospital and Medical Center in Phoenix has received a $3 million donation from Celebrity Fight Night that will be used to help dramatically expand the renowned facility and its programs.

3 Jul 2012

Heart attacks that occur in late pregnancy cause more damage

Heart attacks during pregnancy are uncommon, but the prevalence of heart disease in pregnant mothers has increased over the past decade as more women delay pregnancy until they are older. These women, who are generally less physically active than their younger peers, tend to have higher cholesterol levels and are at greater risk of heart disease and diabetes.

3 Jul 2012

Study examines prevalence of pain among HIV patients in two Ugandan outpatient sites

Sub-Saharan Africa accounts for 69 percent of HIV cases worldwide and 72 percent of AIDS deaths. A study published in The Journal of Pain showed that pain is highly prevalent among well functioning HIV patients in Africa, has a debilitating impact of quality of life, and there is a significant level of unmet need for pain relief.

3 Jul 2012

Sun exposure advice recommended for anti-TNF users

Rheumatology patients using antitumor necrosis factor treatment should be given sun exposure education to reduce their risk for skin cancer, say Irish researchers.

2 Jul 2012

Fighting the physical consequences of jet lag in elite athletes

Research suggests that having a good understanding of preflight, in-flight, and postflight management options helps clinicians, athletes, and coaches minimize the adverse consequences of travel fatigue and jet lag on elite athletic performance.

2 Jul 2012

Obese women draw the hypertension short straw

The associations of obesity with prehypertension and hypertension are stronger in women than men, a study suggests.

2 Jul 2012

Routine use of pelvic CT scans in Wilms tumor questioned

Omitting pelvic computed tomography scans from the routine surveillance of off-therapy patients with Wilms tumor could reduce radiation exposure without compromising relapse detection rates, researchers report.

2 Jul 2012

Three-step clinical pathway for CAP reduces length of hospital stay

A three-step pathway helps to reduce the duration of intravenous antibiotic treatment in hospitalized patients with community-acquired pneumonia, show study findings published in the Archives of Internal Medicine.

2 Jul 2012

Vitamin D–calcium combo reduces mortality in elderly

The results of a meta-analysis of individual patient data show that vitamin D supplementation with calcium reduces mortality rates in the elderly.

2 Jul 2012

Prostate Cancer Center of New Jersey earns ACR-ASTRO accreditation in radiation oncology

The Prostate Cancer Center of New Jersey, a partnership between AKSM/Oncology and the Urology Group of New Jersey (UGNJ), is the latest in a rapidly growing list of prostate-only treatment centers to earn the high honor of a three-year term of accreditation in radiation oncology.

2 Jul 2012

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis in combination with dexamethasone, versus bortezomib with dexamethasone in patients with relapsed multiple myeloma.

2 Jul 2012